News | July 06, 2022
CEPI and Codiak BioSciences partner to develop protective Betacoronavirus vaccine
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
_256_384.png)
Thermo Scientific Direct Mass Technology mode augments Thermo Scientific Q Exactive UHMR Hybrid Quadrupole-Orbitrap mass spectrometers with charge detection capabilities
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Tislelizumab is now approved in nine indications in China
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Subscribe To Our Newsletter & Stay Updated
